Synthesis and Anti-inflammatory Properties of 1α,25-Dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a Hypocalcemic, Stable Metabolite of 1α,25-Dihydroxy-16-ene-20-cyclopropyl-vitamin D3

被引:37
作者
Laverny, Gilles [1 ]
Penna, Giuseppe [1 ]
Uskokovic, Milan [2 ]
Marczak, Stanislaw [2 ]
Maehr, Hubert [2 ]
Jankowski, Pawel [2 ]
Ceailles, Caroline [3 ]
Vouros, Paul [3 ]
Smith, Brenden [4 ]
Robinson, Matthew [4 ]
Reddy, G. Satyanarayana [4 ,5 ]
Adorini, Luciano [1 ]
机构
[1] BioXell, I-20132 Milan, Italy
[2] BioXell Inc, Nutley, NJ 07110 USA
[3] Northeastern Univ, Dept Chem, Barnett Inst, Boston, MA 02115 USA
[4] Epimer LLC, Providence, RI 02906 USA
[5] Brown Univ, Dept Chem, Providence, RI 02912 USA
关键词
VITAMIN-D-RECEPTOR; 1,25-DIHYDROXYVITAMIN D-3; ANALOG; INHIBITION; GROWTH; PARENT; CELLS;
D O I
10.1021/jm801365a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
1 alpha,25(OH)(2)-16-ene-20-cyclopropyl-vitamin D-3 (13) is several fold more potent than the natural hormone 1 alpha,25-dihydroxyvitamin D-3 (1) as an anti-infilammatory agent. Here, we have further analyzed the anti-inflammatory properties of 13, confirming it as the most potent analogue tested within this family. We then determined the structures of all the natural metabolites of 13, including the 24-oxo metabolite 14, and carried out its synthesis. A comparison of 13 with 14 showed a similar induction of the primary VDR target genes CYP24A1 and CAMP and comparable anti-inflammatory properties as revealed by a similar inhibition of TNF-alpha, IL-12/23p40, IL-6, and IFN-gamma production. Interestingly, 14 displays a 3-fold lower calcemic activity in vivo compared to 13. Collectively, these findings indicate that the strong potency of 13 can be explained by the accumulation of its stable 24-oxo metabolite, which shows immunoregulatory and anti-inflammatory properties superimposable, to those exerted by 13 itself.
引用
收藏
页码:2204 / 2213
页数:10
相关论文
共 42 条
[11]   C-6 functionalized analogs of 25-hydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3:: Synthesis and binding analysis with vitamin D-binding protein and vitamin D receptor [J].
Addo, JK ;
Swamy, N ;
Ray, R .
STEROIDS, 1999, 64 (04) :273-282
[12]   Characterization of five 19-nor-analogs of 1α,25(OH)2-Vitamin D3 with 20-cyclopropyl-modified side-chains:: implications for ligand binding and calcemic properties [J].
Olivera, CJ ;
Bula, CM ;
Bishop, JE ;
Adorini, L ;
Manchand, P ;
Uskokovic, MR ;
Norman, AW .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 89-90 (1-5) :99-106
[13]   1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression [J].
Sakai, Sadaoki ;
Takaishi, Hironari ;
Matsuzaki, Kenichiro ;
Kaneko, Hironori ;
Furukawa, Mitsuru ;
Miyauchi, Yoshiteru ;
Shiraishi, Ayako ;
Saito, Keiji ;
Tanaka, Akio ;
Taniguchi, Tadatsugu ;
Suda, Toshio ;
Miyamoto, Takeshi ;
Toyama, Yoshiaki .
JOURNAL OF BONE AND MINERAL METABOLISM, 2009, 27 (06) :643-652
[14]   Double bond in the side chain of 1α,25-dihydroxy-22-ene-vitamin D3 is reduced during its metabolism:: studies in chronic myeloid leukemia (RWLeu-4) cells and rat kidney [J].
Rao, DS ;
Balkundi, D ;
Uskokovic, MR ;
Tserng, KY ;
Clark, JW ;
Horst, RL ;
Reddy, GS .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2001, 78 (02) :167-176
[15]   Synthesis, metabolism, and biological activity of 2-[3-(tetrazolyl)propyl]-1α,25-dihydroxy-19-norvitamin D3 [J].
Takano, Masashi ;
Yasuda, Kaori ;
Higuchi, Erika ;
Tohyama, Eri ;
Takeuchi, Akiko ;
Sakaki, Toshiyuki ;
Kittaka, Atsushi .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2016, 164 :40-44
[16]   Design and synthesis of 2α-(tetrazolylethyl)-1α,25-dihydroxyvitamin D3 as a high affinity ligand for vitamin D receptor [J].
Matsuo, Miki ;
Hasegawa, Asami ;
Takano, Masashi ;
Saito, Hiroshi ;
Kakuda, Shinji ;
Takagi, Kenichiro ;
Ochiai, Eiji ;
Horie, Kyohei ;
Takimoto-Kamimura, Midori ;
Takenouchi, Kazuya ;
Sawada, Daisuke ;
Kittaka, Atsushi .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2014, 144 :201-203
[17]   Tissue specific metabolism of 1α,25-dihydroxy-20-epi-vitamin D3 into new metabolites with significant biological activity:: Studies in rat osteosarcoma cells (UMR 106 and ROS 17/2.8) [J].
Siu-Caldera, ML ;
Rao, DS ;
Astecker, N ;
Weiskopf, A ;
Vouros, P ;
Konno, K ;
Fujishima, T ;
Takayama, H ;
Peleg, S ;
Reddy, GS .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2001, 82 (04) :599-609
[18]   S179D prolactin sensitizes human prostate cancer cells such that physiological concentrations of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death [J].
Wu, Wei ;
Zanello, Laura ;
Walker, Ameae M. .
PROSTATE, 2007, 67 (14) :1498-1506
[19]   New derivatives of 1α,25-dihydroxy-19-norvitamin D3 with two substituents at C-2:: synthesis and biological activity [J].
Shimizu, M ;
Iwasaki, Y ;
Shimazaki, M ;
Amano, Y ;
Yamamoto, K ;
Reischl, W ;
Yamada, S .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (05) :1451-1455
[20]   SYNTHETIC STUDIES OF VITAMIN-D ANALOGS .9. SYNTHESIS AND DIFFERENTIATION-INDUCING ACTIVITY OF 1-ALPHA,25-DIHYDROXY-23-OXA-VITAMIN-D3, THIA-VITAMIN-D3, AND AZAVITAMIN-D3 [J].
KUBODERA, N ;
MIYAMOTO, K ;
AKIYAMA, M ;
MATSUMOTO, M ;
MORI, T .
CHEMICAL & PHARMACEUTICAL BULLETIN, 1991, 39 (12) :3221-3224